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To the Editor: Renal sympathetic denervation (RSD) is an inter-
ventional treatment option for resistant arterial hypertension (HT)
(1). Previous investigations of RSD excluded patients with pro-
gressive chronic kidney disease because of potential RSD-related
kidney damage (1,2). Diagnosis of acute kidney injury is a clinical
challenge; because of the absence of clinical symptoms, the
diagnosis is based on biomarkers. However, a critical problem is
the diagnostic gap for commonly used biomarkers during the early
period after acute kidney injury. Highly sensitive biomarkers, such
as urinary neurophil gelatinase-associated lipocalin (NGAL) and
kidney injury molecule (KIM)-1, are early, maybe even real-time,
markers for the early detection of even minor structural and
functional kidney damage.
The present study analyzed urinary NGAL and KIM-1 con-
centrations, in addition to serum creatinine (sCr), blood urea
nitrogen, and estimated glomerular filtration rate (eGFR), in
patients undergoing RSD. Patients with impaired renal function
(eGFR 45 ml/min/1.73 m2) also were considered. Our objective
was to detect potential RSD-related functional or structural kidney
damage in patients with refractory hypertension during the early
postprocedural period and after a 3-month follow-up.
From September 2011 through March 2012, 62 consecutive
patients with resistant HT who were to undergo RSD were
included in the study at 2 clinical centers. In all patients, renal
artery stenoses and further secondary origins of the HT (3) were
excluded, before RSD. RSD was performed according to the
standard clinical practice using a transfemoral approach with a 6-F
sheath via the femoral artery. All patients received 500 ml 0.9%
NaCl intravenously before and after the procedure. Patients were
followed up over 3 months, and venous blood samples were
collected before and at 24 h, 48 h, and 3 months after RSD.
Samples were processed immediately and were frozen at 80°C
until assayed. Twenty-four–hour blood pressure measurement was
obtained before and 4 weeks and 3 months after RSD. Written
informed consent from all patients for each investigation, as well as
approval from the Institutional Review Board of the University of
Giessen (230/11), was obtained.
A total of 62 consecutive patients (33 men and 29 women, mean
age 68.0  10.4 years) were included. Tables 1, 2, and 3 show the
linical characteristics of all patients enrolled in the study. All RSD
rocedures were performed bilaterally in a single-session proce-
Baseline CharacteristicsTable 1 Baseline Characteristics
n 64
Age, yrs 67.8 10.4
Male 33 (51.6)
Body mass index, kg/m2 29.3 5.3
Number of antihypertensive drugs 5.4 1.4Values are n, mean  SD, or n (%).ure. On average, 78.5  39.0 ml of contrast fluid was adminis-
ered. The average number of antihypertensive drugs was 5.4 1.4
n different substance classes.
A significant systolic blood pressure reduction was observed at 4
eeks as well as at the 3-month follow-up (Table 2). Measurement
f urinary NGAL and KIM-1 concentrations showed no signifi-
ant changes 24 and 48 h after RSD compared with baseline.
urthermore, no significant changes were seen at the 3-month
ollow-up (Table 3). In addition, measurements of eGFR and the sCr
evels showed no significant differences after RSD compared with
aseline. Even 3 months after RSD, these values remained unaltered
Table 3). In particular, 8 patients (13%) had an impaired renal function,
ith eGFR of 45 ml/min/1.73 m2 (37.8  4.3 ml/min/1.73 m2).
Even these patients did not show any alterations regarding KIM-1
and NGAL levels either in the early postprocedural period or after
3 months.
The results of the present study indicate the nonappearance of
RSD-related functional or structural kidney damage or decreases
in the remaining renal function during the early postprocedural
period and after the 3-month follow-up.
Previous investigations excluded patients with impaired renal
function (GFR 45 ml/min/1.73 m2) or progressive chronic
idney disease, because no data were available regarding potential
SD-related functional or structural kidney damage, or both
1–3). We conducted serial measurements of urinary NGAL and
IM-1 concentrations after RSD, in addition to sCr and eGFR
easurements, to look for procedure-related functional and struc-
ural kidney damage after RSD, also considering patients with
mpaired renal function (eGFR45 ml/min/1.73 m2). Our results
emonstrate that urinary NGAL and KIM-1 concentrations did
ot increased during the following 2 days after RSD or after 3
onths follow-up. The same holds true when patients with a eGFR
45 ml/min/1.73 m2 were investigated. In accordance with this
observation, we additionally did not observe alteration in sCR, blood
urea nitrogen, or eGFR measurements.
To our knowledge, this study was the first to investigate
biomarkers for functional or structural kidney damage, or both, at
early time points after RSD. Urinary NGAL and KIM-1 assays
provided incremental diagnostic information, especially in the
early phase of kidney damage, which is not detected by conven-
Blood Pressure and Laboratory MeasurementsTable 2 Blood Pressure and Laboratory Measurements
Blood
Pressure
(mm Hg) Baseline
4 Weeks
After Renal
Denervation
3 Months
After Renal
Denervation
p
Value
Systolic 161.0 14.8 138.0 15.9 135.0 17.1 0.001
Diastolic 79.8 16.5 73.4 10.6 71.3 10.4 0.001
Values are mean  SD.tional biomarkers. Furthermore, KIM-1 and NGAL correlated
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January 29, 2013:479–84positively with the degree of structural kidney damage and nega-
tively with renal function.
Although conventional biomarkers for acute kidney injury such
as sCr and blood urea nitrogen can provide information about
kidney impairment, they have a diagnostic gap that can range from
the first hours to the first days after structural or functional kidney
damage, or both. Therefore, we also analyzed urinary NGAL and
KIM-1 concentrations for the early and highly sensitive detection
of subsequent functional and structural kidney damage with the
potential for progression within the first days, as well as 3 months
after RSD.
Although KIM-1 is not detected in healthy kidneys, in the
present study, concentrations of KIM-1 were increased moderately
at baseline. This may be explained by the fact that all of the
included patients had HT and more than one third of the cohort
had diabetes, which is known to be associated with elevated
KIM-1 levels.
A total of 88.7% of the RSD-treated patients had sufficient
blood pressure reduction after 3 months. Even in patients in whom
RSD was unsuccessful, there were no differences with regard to the
measured markers.
The preserved renal function after RSD may indicate that the
autoregulatory mechanisms of the kidneys are not disturbed by this
interventional procedure. In particular, the RSD-related reduction
in efferent sympathetic activity leads to decreased renin release, and
the effect on the afferent sympathetic fibers results in modulation
of the peripheral vascular tone and reduction in renal blood flow.
In accordance with the safety of the RSD procedure, and as
reported in the HTN-1 Trial (2), the present study found no
evidence of procedure-related kidney damage.
The exclusion of RSD-related functional or structural kidney
damage, or both, is of major clinical importance. Our results
provide additional evidence that RSD in patients with resistant
HT is safe and potentially could be used for patients with
Laboratory MeasurementsTable 3 L bo atory Measurements
Baseline
Durat
24 Hours
Creatinine (mg/dl) 0.90 (IQR: 0.80–1.11) 0.90 (IQR: 0.74–1.10)
eGFR (ml/min/1.73 m2) 79.3 27.3 81.2 24.6
BUN (mg/dl) 39.0 (IQR: 31.8–54.3) 36.0 (IQR: 30.0–48.0)
Urinary NGAL (ng/ml) 16.9 (IQR: 6.8–34.1) 14.0 (IQR: 6.2–39.8)
KIM-1 (ng/ml) 0.65 (IQR: 0.30–0.95) 0.53 (IQR: 0.37–0.82)
BUN  blood urea nitrogen; eGFR  estimated glomerular filtration rate; IQR  interquartile ran
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